Loading
A phase 3 trial of Alectinib, Entrectinib, Durvalumab in non-small-cell lung cancer and small-cell lung cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT05170204 by Hoffmann-La Roche, with 68 participants enrolled, started 2022-11-01 and due to reach its primary completion in 2030-06-16. Interventions recorded: Alectinib, Entrectinib, Durvalumab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Alectinib, Entrectinib, Roche / Genentech, Small-cell lung cancer.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Alectinib, Non-small-cell lung cancer.
Shares Alectinib, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Durvalumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/